Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SURMODICS INC Regulatory Filings 2021

Feb 16, 2021

32845_rns_2021-02-16_a624a0df-2f04-4d2c-b407-f9deddd89e2e.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

February 11, 2021
Date of report (Date of earliest event reported)
Surmodics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Minnesota 0-23837 41-1356149
(State of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
9924 West 74th Street Eden Prairie , Minnesota 55344
(Address of Principal Executive Offices) (Zip Code)
( 952 ) 500-7000
(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)

☐ Pre‑commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))

☐ Pre‑commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, $0.05 par value SRDX Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Shareholders of Surmodics, Inc. (the “Company”) was held on February 11, 2021. The final voting results of the proposals, which were described in more detail in the Company’s proxy statement filed with the Securities and Exchange Commission on December 22, 2020, are set forth below.

  1. Election of Directors . Each of the individuals nominated by the Company’s Board of Directors to serve as Class III directors was duly elected by the Company’s shareholders, and the final results of the votes cast are as follows:
For Withheld Broker Non-Votes
David R. Dantzker, M.D. 11,256,231 295,992 824,386
Lisa W. Heine 11,248,878 303,345 824,386
Gary R. Maharaj 11,444,005 108,218 824,386
  1. Set the Number of Directors . The Company’s shareholders approved the proposal to set the number of directors at six (6) by the following vote:
For Against Abstain Broker Non-Votes
11,508,429 24,001 19,793 824,386
  1. Ratification of the Appointment of Deloitte & Touche LLP . The Company’s shareholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year 2021 by the following vote:
For Against Abstain Broker Non-Votes
12,281,480 75,586 19,543 -
  1. Advisory Vote on Executive Compensation . The Company’s shareholders approved the compensation of the Company’s named executive officers, on an advisory basis, by the following vote:
For Against Abstain Broker Non-Votes
11,234,762 274,983 42,478 824,386

Item 9.01 Financial Statements and Exhibits.

(d)
Exhibit Number Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Gordon S. Weber
Gordon S. Weber
Senior Vice President of Legal, General Counsel and Secretary

EXHIBIT INDEX

Exhibit Number Description
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)